Neville Rodie & Shaw Inc. Decreases Position in Stryker Corporation $SYK

Neville Rodie & Shaw Inc. decreased its stake in Stryker Corporation (NYSE:SYK) by 1.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 2,756 shares of the medical technology company’s stock after selling 50 shares during the quarter. Neville Rodie & Shaw Inc.’s holdings in Stryker were worth $1,090,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of SYK. Capital A Wealth Management LLC purchased a new position in Stryker in the fourth quarter valued at about $26,000. Goodman Advisory Group LLC purchased a new position in Stryker in the first quarter valued at about $32,000. City Holding Co. boosted its holdings in Stryker by 528.6% in the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares during the last quarter. Ransom Advisory Ltd purchased a new position in Stryker in the first quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in Stryker in the first quarter valued at about $40,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Down 1.4%

Shares of Stryker stock opened at $383.32 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The business’s 50 day simple moving average is $388.98 and its 200-day simple moving average is $379.65. The stock has a market capitalization of $146.55 billion, a price-to-earnings ratio of 50.77, a PEG ratio of 2.80 and a beta of 0.93. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is presently 44.50%.

Analyst Ratings Changes

A number of research analysts recently commented on the company. BTIG Research reissued a “buy” rating on shares of Stryker in a report on Monday, July 14th. Needham & Company LLC increased their price target on Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a report on Friday, August 1st. Wells Fargo & Company increased their price target on Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a report on Friday, August 1st. Citigroup restated a “buy” rating and set a $455.00 price objective (up previously from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Friday, July 18th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $431.42.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.